Linagliptin
-
![CAS No:668270-12-0 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-<br />methylquinazolin-2-yl)methyl]purine-2,6-dione](http://www.vvchem.com/structure/cas-668/668270-12-0.png)
Molecular Structure
Detailed Description
Linagliptin ( trade names Tradjenta and Trajenta,cas 668270-12-0) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.Linagliptin (cas 668270-12-0) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.
View Contact Detail